Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News
LucidSearch
QuickAnswers

Contact Us

Search

neuroinflammatory diseases

Neuroscience

Neuroscience Video Recap—December 10, 2025

This biweekly Neuroscience video recap highlights major regulatory wins,…

Neuroscience

Neuroscience Today — December 3, 2025

This week’s Neuroscience update highlights advances in seizure therapeutics,…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Rare Disease News
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Immunology Today—December 10, 2025
Women’s Health Video Recap—December 10, 2025
Neuroscience Video Recap—December 10, 2025
Neuroscience Today — December 10, 2025
Lucid Diligence Brief: SanegeneBio RNAi $110 million Series B

Tags

AAV-SLB101 Achieve Life Sciences AI-designed phages Alligator Bioscience Annamycin ATyr Pharma CAP-002 Cedars-Sinai CHD China in-licensing cyclophosphamide Denosumab DHEA-S ELI-002 Eli Lilly TuneLab European Society of Cardiology exclusivity FDA CRL Fertility & Sterility Ganaplacide GIPR Heidelberg Pharma IBTROZI Icotrokinra inebilizumab Ipsen KOSELUGO Kyinsu Mandos Health MAVENCLAD NHG nmCRPC nusinersen OX40 Prefusion F Preterm birth quetiapine XR Rgenta Therapeutics Skin cancer Strive Health SYMP Syndax syphilis THRβ agonist vimseltinib

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Immunology Today—December 10, 2025
Women’s Health Video Recap—December 10, 2025
Neuroscience Video Recap—December 10, 2025
Neuroscience Today — December 10, 2025
Lucid Diligence Brief: SanegeneBio RNAi $110 million Series B

TAGS

AAV-SLB101 Achieve Life Sciences AI-designed phages Alligator Bioscience Annamycin ATyr Pharma CAP-002 Cedars-Sinai CHD China in-licensing cyclophosphamide Denosumab DHEA-S ELI-002 Eli Lilly TuneLab European Society of Cardiology exclusivity FDA CRL Fertility & Sterility Ganaplacide GIPR Heidelberg Pharma IBTROZI Icotrokinra inebilizumab Ipsen KOSELUGO Kyinsu Mandos Health MAVENCLAD NHG nmCRPC nusinersen OX40 Prefusion F Preterm birth quetiapine XR Rgenta Therapeutics Skin cancer Strive Health SYMP Syndax syphilis THRβ agonist vimseltinib

Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News
LucidSearch
QuickAnswers

© 2025 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy